World Pharma News

Syndicate content
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharm
Updated: 2 days 25 min ago

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson's disease meets primary endpoint

Thu, 01/04/2024 - 11:00
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced today the completion of the 18-month data collection in the Phase Ib clinical trial for AB-1005 (AAV2-GDNF), an investigational gene therapy for treating patients with Parkinson's disease (PD).

Healthy omega-3 fats may slow deadly pulmonary fibrosis

Wed, 01/03/2024 - 11:00
Could healthy fats found in nuts and fish slow the progression of potentially deadly lung scarring known as pulmonary fibrosis and delay the need for lung transplants?

UVA pulmonary researchers looked at the association between blood-plasma levels of omega-3 fatty acids - the heart-healthy fats found in foods such as salmon and flaxseeds - and the progression of pulmonary fibrosis, as well as how long patients could go without needing a transplant.

Newly discovered genetic mutation protects against Parkinson's disease

Tue, 01/02/2024 - 11:00
A previously unidentified genetic mutation in a small protein provides significant protection against Parkinson's disease and offers a new direction for exploring potential treatments, according to a new USC Leonard Davis School of Gerontology study.

The variant, located in a mitochondrial microprotein dubbed SHLP2, was found to be highly protective against Parkinson’s disease; individuals with this mutation are half as likely to develop the disease as those who do not carry it.

Want to quit smoking in 2024?

Mon, 01/01/2024 - 11:00
A new study published in Addiction has found that cytisine, a low-cost, generic stop-smoking aid that has been used in eastern Europe since the 1960s, increases the chances of successful smoking cessation by more than two-fold compared with placebo and may be more effective than nicotine replacement therapy. It has a benign safety profile, with no evidence of serious safety concerns.

Oral peptides: A new era in drug development

Fri, 12/29/2023 - 11:00
For decades, a substantial number of proteins, vital for treating various diseases, have remained elusive to oral drug therapy. Traditional small molecules often struggle to bind to proteins with flat surfaces or require specificity for particular protein homologs. Typically, larger biologics that can target these proteins demand injection, limiting patient convenience and accessibility.

Cancer test shows promise for bringing the benefits of immunotherapy to more patients

Thu, 12/28/2023 - 11:00
Brigham researchers' findings from next-generation sequencing suggest that revising current cancer care guidelines could allow approximately 6,000 more patients in the U.S. to benefit from immunotherapy treatment each year.

Immunotherapy is a highly effective treatment for patients whose cancers harbor mismatch repair deficiency, and a new study identifies more cancer patients who could benefit from this form of therapy.

Organic chemistry research transformed: The convergence of automation and AI reshapes scientific exploration

Wed, 12/27/2023 - 11:00
Recently, National Science Open magazine published online a review article led by Professor Fanyang Mo (School of Materials Science and Engineering, Peking University) and Professor Yuntian Chen (Eastern Institute of Technology, Ningbo). The research team proposed a significant shift towards automation and artificial intelligence (AI) in organic chemistry over the past decade.

Natto consumption suppresses arteriosclerosis

Wed, 12/20/2023 - 11:00
Atherosclerosis, a chronic condition characterized by the accumulation of lipid and inflammatory cells within the blood vessel walls, causes cardiovascular diseases, such as heart disease and stroke. Natto, a food rich in vitamin K2, has shown promise in mitigating cardiovascular diseases by enhancing arterial flexibility and modulating inflammatory responses.

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies

Tue, 12/19/2023 - 11:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company's supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with an accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with food allergy.

Outsize benefit seen in trial of drug for kidney disease

Mon, 12/18/2023 - 11:00
In a clinical trial of patients with chronic kidney disease, an experimental drug significantly reduced albuminuria - albumin in urine, a sign of kidney damage - for 50% of participants. When the experimental drug was paired with a standard-care medication, 70% of participants reportedly experienced a significant reduction in albuminuria.

Pfizer declares first-quarter 2024 dividend

Fri, 12/15/2023 - 11:00
Pfizer Inc. (NYSE: PFE) announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.42 for the first-quarter 2024 dividend, payable March 1, 2024, to holders of the Common Stock of record at the close of business on January 26, 2024.

FDA grants Priority Review to Amgen's tarlatamab application for advanced small cell lung cancer

Thu, 12/14/2023 - 11:00
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab.

Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE®) therapy for the treatment of adult patients with advanced small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Enzymes can't tell artificial DNA from the real thing

Wed, 12/13/2023 - 11:00
The genetic alphabet contains just four letters, referring to the four nucleotides, the biochemical building blocks that comprise all DNA. Scientists have long wondered whether it’s possible to add more letters to this alphabet by creating brand-new nucleotides in the lab, but the utility of this innovation depends on whether or not cells can actually recognize and use artificial nucleotides to make proteins.

AstraZeneca to acquire Icosavax

Tue, 12/12/2023 - 11:00
AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform.

The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX-A12 is a potential first-in- class, Phase III-ready, combination protein VLP vaccine which targets both RSV and human metapneumovirus (hMPV),

Major breakthrough for severe asthma treatment

Mon, 12/11/2023 - 11:00
A landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids which can have significant side effects.

The findings from the multinational SHAMAL study, published in The Lancet, demonstrated that 92% of patients using the biologic therapy benralizumab could safely reduce inhaled steroid dose and more than 60% could stop all use.

FDA approves first gene therapies to treat patients with sickle cell disease

Fri, 12/08/2023 - 19:00
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy.

Bayer and Salus Optima partner on AI-enabled healthy aging journey

Thu, 12/07/2023 - 11:00
Salus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.

The risk of cardiovascular disease can be reduced by eating more oily fish

Wed, 12/06/2023 - 11:00
People with close relatives who have suffered from cardiovascular disease may benefit from eating more oily fish. This is according to a new study led by researchers from Karolinska Institutet, published in the journal Circulation.

Oily fish such as salmon, mackerel, herring and sardines contain the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

New technique efficiently offers insight into gene regulation

Tue, 12/05/2023 - 11:00
Researchers from the group of Jop Kind developed a new technique called MAbID. This allows them to simultaneously study different mechanisms of gene regulation, which plays a major role in development and disease. MAbID offers new insights into how these mechanisms work together or against each other. The results were published in Nature Methods on the 4th of December.

Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity

Mon, 12/04/2023 - 11:00
Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.